Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Glaxo Wellcome

This article was originally published in The Tan Sheet

Executive Summary

Glaxo Wellcome: Glaxo Inc. President and CEO Robert Ingram appointed to the board of London-based Glaxo Wellcome plc. Ingram joined Glaxo in 1990 and was named CEO in March 1994. Prior to joining Glaxo, Ingram served as president of Merck Frosst Canada Inc. and VP-government affairs at Merck and Co. The London parent also announces the resignation of former Glaxo Chairman Charles Sanders, MD, as a director after six years on the board. Sanders had resigned from the chairman post May 1 to concentrate full-time on his U.S. Senate campaign...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel